晚期驱动基因阳性非小细胞肺癌免疫治疗专家共识(2022版)

Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations(2022 edition)

驱动基因阳性非小细胞肺癌既往被认为是免疫治疗"禁区",但随着对靶向药物免疫调节作用的深入认识及临床证据的不断生成,免疫治疗有望为驱动基因阳性非小细胞肺癌带来新希望。中国抗癌协会肿瘤精准治疗专业委员会和中华医学会杂志社肺癌研究协作组共同组织肿瘤科、呼吸科、病理科专家对驱动基因阳性人群免疫相关肿瘤及微环境特征和临床治疗的循证医学证据进行深入探讨,并结合专家组广泛认可的临床经验,经过共识会议制定了驱动基因阳性非小细胞肺癌免疫治疗专家共识,旨在为中国临床医师的免疫治疗实践提供规范化指导。

Non-small cell lung cancer(NSCLC)with oncogenic driver mutations was previously deemed"forbidden territory"for immunotherapy.With the growing understanding of the impact of target drugs on the immune microenvironment and the continuous generation of clinical evidence,immunotherapy is expected to bring new hope for the NSCLC patients with oncogenic driver mutations.An expert panel of medical oncology,respiratory medicine and pathology organized by the Society of Cancer Precision Medicine of Chinese Anti-Cancer Association and Expert Group on Lung Cancer of Chinese Medical Journal conducted an in-depth discussion on current evidence of immune microenvironment and clinical studies and formulated a Chinese expert consensus on immunotherapy for advanced NSCLC with oncogenic driver mutations by combining with clinical experience.This expert consensus aims to provide guidance for Chinese clinicians on immunotherapy in NSCLC with oncogenic driver mutations.